Summary Navelbine (NVB, vinorelbine ditartrate, KW-2307), a new vinca alkaloid analogue, has been shown to be clinically effective against advanced breast cancer. In this report, the combined effect of NVB with medroxyprogesterone acetate (MPA), a synthetic progesterone derivative, was examined in vitro against human breast carcinoma MCF-7 cells. The combined effect was demonstrated to be synergistic using the isobologram and median-effect plot analyses. To elucidate the mechanism of action, we further examined effects of both drugs on cell cycle distribution of the cells in combination and/or alone. NVB at 2 nm induced apparent G1-phase accumulation as well as the induction of cyclin-dependent kinase (CDK) inhibitor p21WAF1/cIPl protein and the dephosphorylated form of retinoblastoma protein (pRb). In contrast, MPA at 0.1 gM also induced G1-phase accumulation as well as the reduced expression of cyclin Dl protein. In addition, the combination of both drugs induced augmented G1-phase accumulation, which occurred along with p21WAF1/cIPl protein induction, cyclin Dl protein reduction and pRb dephosphorylation. These results demonstrate that the synergistic combined effect of NVB with MPA was mediated through enhancement of G1-phase accumulation that resulted from the different action point(s) of each drug. Furthermore, the synergistic combined effect of NVB with MPA was also observed in other human breast carcinoma cell lines, such as T-47D and ZR-75-1. These results suggest that combination therapy of NVB with MPA in breast cancer might be effective in clinical studies.
Navelbine (NVB, vinorelbine ditartrate, KW-2307) is a new vinca alkaloid analogue that has been shown to be clinically active against advanced and/or metastatic breast cancer as a single agent (Bruno et al, 1995; Gasco et al, 1997; Livingston et al, 1997) . The drug has been also shown to exert objective clinical outcome in combination with other chemotherapeutic agents, such as doxorubicin, mitomycin C and ifosfamide as a first-line or second-line therapy for advanced breast cancer (Agostara et al, 1994; Spielmann et al, 1994; Hochster, 1995; Pronzato et al, 1997) .
Medroxyprogesterone acetate (MPA) is a synthetic progesterone derivative that has been shown to be clinically effective against advanced breast cancer as a second-line hormonal therapy after tamoxifen (Pannuti et al, 1979; Becher et al, 1989) . MPA has also been shown to augment the efflcacy of combined chemotherapeutic modality for breast cancer [such as cyclophosphamide doxorubicin and 5-fluorouracil (CAF)] and to ameliorate sideeffects caused by chemotherapeutic agents (Hupperets et al, 1993; Tominaga et al, 1994) , thus establishing chemohormonal therapy.
Based on these findings, we have asked whether the combination of NVB with MPA, as a chemohormonal therapy, would be valuable, using cultured human breast carcinoma MCF-7 cells in vitro. Isobologram analysis as well as median-effect plot analysis revealed that the combined effect of NVB with MPA was apparently synergistic. As NVB is known to inhibit the assembly of microtubles, thus inducing mitotic arrest in the cells (Gomi et al, (Sutherland et al, 1988) , we examined the effect of the combination of both drugs on cell cycle distribution of MCF-7 cells.
Unexpectedly, NVB showed GI-phase accumulation both alone and in combination with MPA. Under these circumstances, to examine the mechanism of action of G1-phase accumulation, we have also asked whether NVB and/or MPA affects the expression level of the cell cycle-regulatory proteins such as G, cyclin and p21WAFI/CIPI.
MATERIALS AND METHODS Drugs and reagents
Navelbine (NVB, vinorelbine ditartrate, KW-2307) and medroxyprogesterone acetate (MPA) were obtained from Kyowa Hakko Kogyo, Tokyo, Japan. NVB was dissolved in dimethyl sulphoxide (Wako Pure Chemical Industries, Osaka, Japan). MPA was dissolved in ethanol (Kanto Chemical, Tokyo, Japan). Tris hydroxy aminomethane and Tween 20 were purchased from Bio-Rad Laboratories, Hercules, CA, USA. Sodium chloride, sodium fluoride and ethylenediamine tetra acetic acid (EDTA) were purchased from Kanto Chemical. Triton X-100 was purchased from Yoneyama Yakuhin Kogyo, Osaka, Japan. N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid (HEPES), P-glycerophosphate, sodium o-vanadate, phenylmethylsulphonyl fluoride, aprotinin and leupeptin were purchased from Sigma Chemical, St Louis, MO, USA. Anti-pRb and anti-p21wAFl/cIPl monoclonal antibodies were purchased from PharMingen, San Diego, CA, USA. Anti-cyclin Dl monoclonal antibody was purchased from IBL, Gunma, Japan, and anti-cyclin E monoclonal antibody was purchased from Santa Cruz Biotechnology, Santa Cruz, CA, USA. Anti-cyclin A and anti-CDK2 monoclonal antibodies were prepared as described previously (Akiyama et al, 1997) .
Cell culture MCF-7 (Soule et al, 1973) , T-47D (Keydar et al, 1979) , BT-474 (Lasfargues et al, 1978) and MDA-MB-453 (Cailleau et al, 1978) cells were purchased from the American Type Culture Collection, Rockville, MD, USA. ZR-75-1 cells (Engel et al, 1978) were purchased from the American Type Culture Collection through Dainippon Pharmaceutical, Osaka, Japan. MCF-7, T-47D and ZR-75-1 cells were passaged in RPMI-1640 medium (Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum (Filtron, Brooklyn, Australia), 100 IU penicillin, 100 ,ug ml-1 streptomycin (Gibco) and 10 nM 17p-estradiol (Sigma) at 37°C in a humidified atmosphere containing 5% carbon dioxide in air. BT-474 cells was passaged in the above medium containing 10 jg ml-1 insulin (Sigma) at 37°C in a humidified atmosphere containing 5% carbon dioxide in air. MDA-MB-453 cells were passaged in L-15 medium (Sigma) containing 10% fetal bovine serum, 100 IU penicillin and 100 jig ml-' streptomycin at 37°C in a humidified atmosphere.
Growth-inhibitory activity MCF-7 cells (5 x 103 per 0.5 ml per well) were precultured in the culture medium for 24 h in 24-well multidishes (Nunc, Roskilde, Denmark). Then the cells were treated with the drug(s) for the period indicated in the text. The drug treatment was terminated by washing the cells with phosphate-buffered saline without calcium [PBS(-)] (ICN Biomedicals, Aurora, OH, USA), and the cells were placed in drug-free medium. The cell number was counted using a micro-cell counter (F-300; Toa Medical Electronics, Hyogo, Japan) after the treatment of the cells with 0.05% trypsin (Difco Laboratories, Detroit, MI, USA)/0.02% EDTA solution. Analysis of the combined effect using the isobologram method Cells were precultured in the culture medium for 24 h in 96-well microwell plates (Nunc). Then, the cells were exposed to drugs according to the following schedules: simultaneous exposure to both drugs for 144 h, sequential exposure to NVB for 24 h followed by MPA for 120 h and sequential exposure to MPA for 120 h followed by NVB for 24 h. Cell viability was determined by MTT assay (Mosmann, 1983) . The combination effect of NVB with MPA was assessed by means of isobologram analysis (Berenbaum, 1981) .
Analysis of the combined effect using the median-effect plot method MCF-7 cells (2.5 x 103 per 0.25 ml per well) were precultured in the culture medium for 24 h in 24-well multidishes. The cells were exposed to both drugs for 144 h. The growth-inhibitory activity was evaluated by counting cell number using a micro-cell counter after separating the cells by treatment with trypsin-EDTA solution.
The combined effect of both drugs was determined by medianeffect plot analysis (Chou and Talalay, 1984 (Rosenblatt et al, 1992) for 20 min at 4°C. The cell lysates were clarified by centrifugation at 14 000 r.p.m. for 10 min at 4'C and the protein contents were determined using the protein assay kit (Bio-Rad Laboratories). Equal amounts of protein were heated in sodium dodecyl sulphate (SDS) sample buffer (Laemmli, 1970) for 5 min at 95°C, subjected to SDS-polyacrylamide gel electrophoresis and transferred onto p-membranes (AlTO, Tokyo, Japan). The membranes were incubated in blocking buffer [5% skim milk (Yukijirushi Nyugyo, Hokkaido, Japan) in Tris-buffered saline], probed with primary antibodies followed by secondary antibody conjugated with horseradish peroxidase British Journal of Cancer (1998) 
RESULTS
Kinetic analysis of cell growth-inhibitory activity of NVB and MPA
We carried out kinetic analysis of the cell growth-inhibitory activity of NVB and MPA to determine whether the growthinhibitory activity of both drugs was AUC dependent or time dependent (Gomi et al, 1992) . As shown in Figure 1 Figure 2A and D), sequential exposure to NVB followed by MPA ( Figure 2B and E) and sequential exposure to MPA followed by NVB ( Figure 2C and F) (Figure 2A -C, compared with Figure 2D -F). The combined effect of NVB with MPA was also assessed using median-effect plot analysis. For the analysis, 1.5-fold dilutions of the two drugs were prepared (0.53-6.08 nM NVB and 10.7-122 nM MPA), and they were combined with each other from the lowest concentration (Figure 3) . The combination index (CI) values of the group treated with NVB and MPA were less than 1 at the wide range of concentrations ( Figure 3B ), indicating that the growth-inhibitory activity in the combination regimen was synergistic (Chou and Talalay, 1984) , consistent with the results of the isobologram analysis.
Growth curve of MCF-7 cells treated with both drugs To set up the condition for cell cycle analysis, the growth pattern of MCF-7 cells was examined by simultaneous treatment of the cells with NVB and MPA for 144 h. Combination of 0.5 nm NVB with 0.1 gM MPA showed no combined effect ( Figure 4A ), however the combination of 1 nm or 2 nm NVB with 0.1 ,UM MPA exhibited synergistic growth inhibition ( Figure 4B and C) . When 4 nm NVB was combined with 0.1 ,UM MPA, the growth-inhibitory effect was similar to that of NVB alone ( Figure 4D (Weinberg, 1995) . As shown in Figure 6A , in untreated exponentially growing MCF-7 cells, pRb was constitutively hyperphosphorylated and migrated slower than the underphosphorylated form in SDS-polyacrylamide gel (Weinberg, 1995) . After a 24 h exposure of the cells to 2 nM of NVB, the accumulation of dephosphorylated, faster migrating pRb was observed ( Figure 6A ). In contrast, MPA treatment showed no effect on phosphorylation state of pRb. Combination of NVB plus MPA also induced the accumulation of dephosphorylated pRb in the cells, as was the case for NVB alone.
Recent results have shown that vinca alkaloid compounds, such as vinblastine, can induce the expression of CDK inhibitor p21wAF1/CIPI (Tishler et al, 1995) . Under these circumstances, we tested whether NVB, which is also a vinca alkaloid compound, could induce the expression of p2lwAFI/CIPI in the cells using the Western blotting method. As shown in Figure 6B , NVB did induce the expression of p2lwA"1/ciPl protein in the cells (Figure 6B ), however MPA showed little, if any, effect on the expression level of p2lWAF1/CIPT. Combination of NVB with MPA showed more profound induction of p21wAFI/cIP1 expression than such each drug alone ( Figure 6B ).
We also examined the phosphorylation state of CDK2 protein, which is one of the major Rb kinases in mammalian cells (Sherr and Roberts, 1995) . As shown in Figure 6C , NVB treatment induced the decrease of the faster migrating protein band that was previously shown to be an active and threonine 160-phosphorylated form of CDK2 protein (Schnier et al, 1994) in MCF-7 cells. However, MPA treatment exhibited no effect on mobility of CDK2 protein in the SDS gel. The combination of NVB with MPA showed the same magnitude of reduction on active CDK2 protein as NVB alone ( Figure 6C ).
Combined effect of NVB with MPA on the expression of cyclin proteins Cyclin Dl, E and A proteins have been reported to be expressed and to be degraded depending on cell-cycle phase in breast cancer cells from G, to S-phase (Sutherland et al, 1995) . Namely, cyclin Dl protein is induced at early to mid G,-phase, cyclin E protein is induced at mid to late G,-phase and cyclin A protein induction occurs at late GI-phase to S-phase. To elucidate the arrest point of MCF-7 cells treated with NVB and/or MPA in cell cycle phase, we determined the expression levels of these cyclin proteins after treatment with NVB and/or MPA using the Western blotting method. As reported previously (Sutherland et al, 1995) , MCF-7 cells were confirmed to express all the cyclin proteins tested and the expression of cyclin Dl protein was most abundant ( Figure  6D-F) . Treatment of the cells with 2 nm of NVB for 24 h showed no effect on the expression level of both cyclin Dl and cyclin E protein, while the expression level of cyclin A protein was markedly reduced to a very low or undetectable level ( Figure  6D-F) . In contrast to these effects induced by NVB, MPA treatment of the cells produced marked reduction of cyclin Dl protein level after 24 h, however the expression levels of cyclin A and cyclin E protein were totally unchanged. Combination of NVB plus MPA produced the reduced expression of cyclin DI as well as cyclin A protein, to the same extent as MPA or NVB alone without any effect on cyclin E protein level ( Figure 6D-F) .
Isobologram analysis of the combined effect of NVB with MPA for several breast cancer cell lines
The combination effect of NVB with MPA was further assessed using isobologram analysis by simultaneous exposure to both drugs for 144 h, using several human breast cancer cell lines, to British Journal of Cancer (1998) MPA alone (C). Cell fixation, RNA hydrolysis and DNA staining with propidium iodide were performed as described in Materials and methods. DNA histograms were produced using flow cytometry elucidate whether the combination effect was a general phenomenon in other human breast cancer cell lines. We used oestrogen receptor (ER)-and progesterone receptor (PR)-positive cell lines, such as T-47D, ZR-75-1 and BT-474 (Sutherland et al, 1988) , and ER-and PR-negative cell line MDA-MB-453 (Hall et al, 1994) . As BT-474 and MDA-MB-453 cell lines failed to respond to the growth-inhibitory effects of MPA alone, IC50 of NVB was not affected by MPA. In T-47D and ZR-75-1 cell lines, which are sensitive to MPA alone, the isobologram analysis of the combination revealed that the combined effect was additive or synergistic (Table 1) .
DISCUSSION
Recent studies suggest that hormonal therapy combined with chemotherapy termed chemohormonal therapy is expected to be more beneficial than either of the therapies alone for advanced or recurrent breast cancer (Tominaga et al, 1994) . To rationale for the combination modality of NVB, which has been shown to be clinically effective against advanced breast carcinoma, with MPA, one of the established therapies for tamoxifenresistant advanced breast carcinoma, we have assessed the combined effect of both drugs using the cultured human breast carcinoma cell line MCF-7 in vitro.
Results from classical isobologram analysis (Figure 2 ) as well as median-effect plot analysis (Figure 3) revealed that the combined effect of NVB with MPA was synergistic over a wide range of their concentrations against cultured human breast carcinoma MCF-7 cells. NVB has been shown to bind to tubulin, to prevent tubulin polymerization and to induce M-phase block on cell cycle in target cells (Fellous et al, 1989; Gomi et al, 1992) . In contrast, MPA has been shown to lead to G,-phase accumulation of MCF-7 cells through unknown mechanism(s) (Sutherland et al, 1988) . We therefore suspected that regulation of cell cycle progression might play an important role on mechanism(s) of action of the combined effect of NVB with MPA, and we have tested the effect of NVB and/or MPA on cell cycle distribution of MCF-7 cells. As reported previously, MPA showed apparent GI-phase accumulation of MCF-7 cells at 0.1 and 1 ,UM ( Figure 5A and C) . Surprisingly, NVB also induced G,-phase accumulation at 2 nM, which is a near 50% growth-inhibitory concentration against MCF-7 cells, as shown in Figure SA . The drug also induced G,-phase accumulation at 4 nm, which is near a 90% growth-inhibitory concentration ( Figure SB) . Combination of 2 nM NVB plus 0.1 JIM MPA also induced apparent G,-phase accumulation in MCF-7 cells (Figure 5 ), which was more profound than each drug alone, suggesting that the synergistic combined effect of NVB and MPA might be mediated through enhanced G,-phase accumulation. To gain some more insight into G,-phase accumulation induced by each drug alone and the combination of both drugs, we assessed the effect of NVB and/or MPA on the expression and phosphorylation state of cell cycle-regulatory proteins, such as Rb, p21WAFI/CIPI, CDK2 and G, cyclins. NVB (2 nM) induced dephosphorylated pRb and CDK2 protein as well as induction of CDK inhibitor protein p21wAFl/cwPl in the cells, which was coincident with G,-phase accumulation ( Figure 6A-C) . Treatment of cells with 4 nM of NVB also induced dephosphorylated pRb and the expression of p21WAFI/CIPI protein (data not shown). In contrast to these effects of NVB, 0.1 JIM of MPA had no effect on these cell cycle-regulatory proteins ( Figure 6A-C) . Regarding the expression of G, cyclin proteins, which constitutes a cell cycle marker in mammalian cells, NVB showed the apparent reduction of cyclin A, which is a late G, to S and G2-phase marker, without any effect on cyclin Dl and E ( Figure 6D-F) , suggesting that NVB accumulated the cells in late G,-phase of the cell cycle. MPA induced a substantial reduction in the expression of cyclin Dl protein without any effect on cyclin E and A ( Figure 6D-F) . Combination of NVB plus MPA induced an additive effect on dephosphorylation of pRb and CDK2 protein and reduction of cyclin Dl and A, however the induction of p21wA"IlCIPl might be synergistic (Figure 6 ). These results suggest that the differential effect of each drug alone on cell cycle-regulatory proteins might be important for the synergistic combined effect.
Interestingly, recent reports have shown that mitotic poisons, such as vinblastine (a vinca alkaloid compound) and taxol, could induce the expression of p53 and p21WAF1/CIP1 in MCF-7 and NIH3T3 cell lines (Blagosklonny et al, 1995; Tishler et al, 1995 Tishler et al, , 1996 . Although these authors did not mention the effect of vinblastine and/or taxol on cell-cycle distribution, it is quite reasonable to suggest that these drugs exhibit G,-phase accumulation through induction of p21WAF1/CIP1. In addition, there is a report showing that taxol could induce G,-phase accumulation in normal rat fibroblast cells (Trielli et al, 1996) . From these recent reports of the effects of mitotic poisons on the cell cycle, it might be reasonable to expect that NVB would induce G,-phase accumulation in cultured human cells, although its mechanism(s) of action remains to be determined.
Regarding the mechanism(s) of action of G,-phase accumulation induced by MPA, there is no explanation for this effect. As cyclin Dl has been reported to regulate G, to S-phase progression in mammalian cells (Jiang et al, 1993) and to also act as an oncogene (Motokura et al, 1991) , our results suggest that reduction of cyclin Dl protein might play an important role in G,-phase accumulation induced by MPA (Figure 6 ). In addition, recent results British Journal of Cancer (1998) 77(11), [1737] [1738] [1739] [1740] [1741] [1742] [1743] showed that cyclin DI could activate oestrogen-responsive elements in an oestrogen-independent manner in cultured breast carcinoma cells (Zwijsen et al, 1997) . More studies are needed on the detailed mechanism(s) of action for MPA-induced G,-phase accumulation.
We also studied the combined effect of NVB with MPA using several human breast cancer cell lines to elucidate whether the combined effect was a general phenomena in human breast cancer cell lines. As BT-474 and MDA-MB-453 cell lines were insensitive to MPA alone, we could not detect any combined effect. In T-47D and ZR-75-1 cell lines, which were sensitive to MPA alone, the isobologram analysis revealed that the combined effect was additive or synergistic ( Table 1 ), suggesting that the combination of NVB with MPA might be effective against human breast cancer that is sensitive to MPA alone.
In conclusion, our studies suggest that the combination of NVB with MPA should be considered as a candidate for clinical trials for advanced breast cancer.
